Uncategorized
FDA grants orphan drug designation for ISTH0036 to Isarna
The FDA has granted orphan drug designation for ISTH0036 for the prevention of scarring after glaucoma filtration surgery, Isarna Therapeutics announced in a press release.The FDA decision follows recent EMA orphan drug designation for ISTH0036, which is currently in phase 1 evaluation in glaucoma patients, the release said.